on Heidelberg Pharma AG (ETR:HPHA)
Heidelberg Pharma's Annual General Meeting 2026 Overview
Heidelberg Pharma AG held its Ordinary Annual General Meeting on June 23, 2026. Shareholders approved all management proposals with substantial majorities, ranging from 98.67% to 98.72%. Key resolutions included formally approving the Management and Supervisory Boards for the 2024/2025 financial year and appointing auditors for 2025/2026.
Notably, Jack Yefei Ling was elected as a new member of the Supervisory Board. Additionally, a resolution was passed to reduce the size of the Supervisory Board from seven to five members. Attendance at the meeting, including postal votes, represented 80.55% of the capital stock.
Heidelberg Pharma, based in Ladenburg, Germany, focuses on developing Antibody Drug Conjugates (ADCs) and is publicly traded on the Frankfurt Stock Exchange.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Heidelberg Pharma AG news